Address: 823 Jays Drive
Lansdale, PA 19446,United States of America
Tel:
Web: http://www.jdptherapeutics.com/default.aspx
JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life-threatening diseases with significant unmet medical needs, primarily for use in acute care in a hospital setting.
Small Molecule Therapeutics
Alper Ureten, Amgen VP and General Manager, sits down with PharmaBoardroom to set out his ambitions and objectives for its Biosimilars Business Unit. Ureten also reveals the strategy behind their…
William H Lewis, chairman and CEO of serious and rare disease specialist Insmed, talks through the impact of recent product approvals in the US, preparations underway for international launches, the…
Ulrich Neumann examines the debate around drug pricing in the US and why it is not going away any time soon. Come senators, congressmen Please heed the call Don’t…
John G. Singer examines why technological solutions are not a quick fix to overcoming the COVID-19 crisis and how a systems shift is crucial to securing better health outcomes in…
Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but innovative concepts are finally emerging. We will have to move beyond siloed thinking to…
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA approvals. Although launching new products in the midst of a global pandemic…
Dan Leonard, Kimberly Westrich, and Brian Sils of the National Pharmaceutical Council examine how a new HHS ruling on how US patients pay for medicines could hurt them financially, exacerbating…
Dr Brett Monia, co-founder and CEO of RNA therapeutics pioneer Ionis Pharmaceuticals, outlines the company’s extremely promising development pipeline, commercial partnerships with Big Pharma, and his ambitious strategy to launch…
Christopher Posner, US head for Danish medical dermatology specialist LEO Pharma, outlines how a mid-sized European company navigates the US market’s complex access and affordability issues, the innovations that the…
Two leading executives in the US generics market outline why robust company culture is key to attracting top talent that might otherwise gravitate towards the traditional research-driven industry. Talent…
In a recent virtual town hall meeting hosted by BIO, two key leaders from the US FDA laid out how their organisation has adjusted in the wake of the COVID-19…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND)…
See our Cookie Privacy Policy Here
